CTOR vs MELI · $105.2M cap vs P/E 43, rev $20.78B
Citius Oncology, Inc. (CTOR) versus MercadoLibre Inc. (MELI) — a side-by-side from cached financials, not a winner call.
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on US.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
CTOR does not have a complete income-statement cache yet.
Latest reported MELI revenue for 2024-12-31 was $20.78B. Net income was $1.91B. Revenue was up 387.6% from 2023-12-31 to 2024-12-31. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
CTOR currently screens at market cap $105.2M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Not investment advice. Open the CTOR and MELI stock pages for the full models.
Not investment advice.